SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma
Autors principals: | Chiara Rusconi, Giulio Cassanello, Anna Guidetti, Chiara Oltolini, Vincenzo Marasco, Lucio Morabito, Matteo Della Porta, Rodolfo Lanocita, Gabriele Papagni, Cristiana Carniti, Paolo Corradini |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
Wiley
2020-10-01
|
Col·lecció: | HemaSphere |
Accés en línia: | http://journals.lww.com/10.1097/HS9.0000000000000472 |
Ítems similars
-
P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
per: Chiara Rusconi, et al.
Publicat: (2022-10-01) -
P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
per: Chiara Rusconi, et al.
Publicat: (2023-08-01) -
P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
per: Chiara Rusconi, et al.
Publicat: (2022-10-01) -
Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease
per: Otsuji N, et al.
Publicat: (2024-06-01) -
Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections
per: Paolo Corradini, et al.
Publicat: (2020-06-01)